In this research, cost-effectiveness analysis was performed using published data. Therefore patient enrollment did not occur.
The target population of the current analysis was the population of previously untreated patients with DLBCL in the POLARIX trial.
[Primary] The ICER for Pola+R-CHP combination therapy compared to R-CHOP therapy was JPY2,710,238 per QALY.
[Secondary(1)]For patients who received Pola+R-CHP combination therapy, the expected cost from the start of first-line treatment until the end of end-of-life care was JPY34,917,885and the expected effectiveness was 11.25 QALYs.
[Secondary(2)]The expected cost for patients who received R-CHOP therapy was JPY33,889,314 and the expected effectiveness was 10.87 QALYs.
The incremental cost-effectiveness ratio (ICER) of Pola+R-CHP versus R-CHOP was JPY2,710,238 per quality-adjusted life year (QALY), less than the ICER of JPY7.5 million per QALY that is considered to be cost-effective based on the threshold of the Japanese cost-effectiveness evaluation system. This study suggests that Pola+R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.